Accent Capital Management’s Moderna MRNA Stock Holding History

Accent Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25	Closed	-$690	–	409
2025 Q2	$690	Buy	+25	New	+$658	﹤0.01%	394

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Accent Capital Management's MRNA Position: Q3 2025 in Review

Accent Capital Management sold out of Moderna (MRNA) in Q3 2025, closing a stake of 25 shares — an estimated $690 sold.

Accent Capital Management first reported a position in MRNA in Q2 2025 and held it in 1 quarter. The position peaked at $690 in Q2 2025. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

Accent Capital Management reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
Accent Capital Management sold 25 Moderna shares in Q3 2025, an estimated $690.
Accent Capital Management first reported a position in Moderna in Q2 2025 and held it in 1 quarter.
Accent Capital Management's Moderna position peaked at $690 in Q2 2025.
643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Accent Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.